GSK

Prezzo: 53.04

Società e modello di business

GSK is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products. Its core products include prescription medications for various therapeutic areas, vaccines for infectious diseases, and over-the-counter consumer health products. Major business segments consist of Pharmaceuticals, Vaccines, and Consumer Healthcare, with revenue primarily generated from prescription drugs and vaccines. The company aims to address health challenges through innovation and research.

Profilo di investimento

GSK's stock presents a neutral investment profile, appealing to investors seeking a balance between growth and dividends. The company offers a moderate dividend yield, which may attract income-focused investors, while its pharmaceutical innovations suggest potential for future growth. However, recent revenue declines indicate caution for growth-oriented investors. Overall, it may suit those looking for stability rather than aggressive growth.

Sito ufficiale

Metriche fondamentali (sperimentale)

EPS (TTM) — utile per azione degli ultimi 12 mesi, $: 3.42 OK
Ricavi QoQ — crescita dei ricavi trimestre su trimestre: -11.5% ↓
Sorpresa EPS: 6.9% meglio del previsto
Volatilità 20g: 1.5% stabile
Rendimento dividendo: 3.5% moderato ultima data ex-dividendo: 2026-05-15

Dati FMP / FinFeed aggiornati: 2026-06-10

Racc.: Compra Potenziale: 63 Rischio: 42 Aggiornato: 2026-06-13 02:53

Come funziona la raccomandazione

Perché l'AI la pensa così:

Stable dividend, but revenue decline raises concerns.

Traccia in portafoglio

Grafico prezzo

Raccomandazione AI Previsione analista Evento calendario Segnale positivo Segnale negativo Neutrale / aggiornamento Mantieni / informativo B My buy S My sell

Cambiamenti di raccomandazione AI

Data	Prima	Dopo	Motivo
2026-06-13 02:53	Mantieni	Compra	Stable dividend, but revenue decline raises concerns.
2026-05-28 02:46	Vendi	Mantieni	Weak fundamentals and mixed momentum signal caution.
2026-05-20 02:45	Mantieni	Vendi	Weak fundamentals and negative momentum raise concerns.
2026-05-08 15:09	—	Mantieni	Weak momentum and fundamentals raise significant risk concerns.
2026-05-08 05:34	Mantieni	Mantieni	Компания GSK демонстрирует высокую дивидендную доходность и положительный рост за 120 дней, однако недавние падения цен и отрицательная динамика выручки вызывают опасения.
2026-04-25 02:54	Compra	Mantieni	Компания показывает умеренный рост за последние месяцы, однако недавнее снижение цены может указывать на краткосрочные риски. Дивидендная доходность также привлекательна, что делает акцию интересной для долгосрочных инве
2026-03-17 17:10	Mantieni	Compra	Компания GSK демонстрирует положительную динамику на длительном горизонте, с ростом на 31.43% за 120 дней, а также стабильный дивидендный доход в 3.30%. Несмотря на недавние колебания, потенциал роста и сильные финансовы
2026-03-09 07:39	Compra	Mantieni	Компания GSK демонстрирует устойчивый рост за последние 120 дней, однако недавнее снижение цен и отрицательная динамика выручки могут указывать на краткосрочные риски. Рекомендуется удерживать акции до прояснения ситуаци
2026-01-22 08:35	Mantieni	Compra	Компания GSK показывает положительную динамику на длительном горизонте, особенно за последние 120 дней. Несмотря на недавние колебания, её рост и стабильность в секторе здравоохранения делают её привлекательной для инвес

Previsioni analisti

Data	Analista	Action	Target	Prezzo allora
2025-10-30 11:27	CFRA	Aggiorna	— → 53	46.67

Stocks to Watch: Nuvalent Soars on GSK Acquisition Announcement, J.M. Smucker Reports Strong Earnings, SailPoint Issues Weak Guidance

06/09/2026, 05:33 AM business review J.M. Smucker Company Micron Technology GSK Alibaba Vail Resorts Qualcomm

Nuvalent's shares surged nearly 39% following GSK's announcement of a $10.6 billion acquisition, highlighting significant market activity in the pharmaceutical sector. Meanwhile, J.M. Smucker's strong earnings report positively impacted its stock, while SailPoint's disappointing guidance led to a notable decline in its shares.

GSK in Negotiations to Acquire Oncology Biotech Nuvalent for Over $9 Billion

06/08/2026, 10:31 PM business announcement GSK

GSK is negotiating to acquire Nuvalent for over $9 billion, marking its largest acquisition in over a decade, which could significantly enhance its oncology portfolio and address investor concerns about its drug pipeline.